Morepen Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Morepen Laboratories has a total shareholder equity of ₹7.9B and total debt of ₹277.6M, which brings its debt-to-equity ratio to 3.5%. Its total assets and total liabilities are ₹11.9B and ₹4.1B respectively. Morepen Laboratories's EBIT is ₹1.1B making its interest coverage ratio 58.4. It has cash and short-term investments of ₹578.4M.
Key information
3.5%
Debt to equity ratio
₹277.55m
Debt
| Interest coverage ratio | 58.4x |
| Cash | ₹578.44m |
| Equity | ₹7.89b |
| Total liabilities | ₹4.05b |
| Total assets | ₹11.94b |
Recent financial health updates
Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23
Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03
We Think Morepen Laboratories (NSE:MOREPENLAB) Can Stay On Top Of Its Debt
Jul 29Recent updates
Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing
Apr 23Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 22Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 21Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Apr 05Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?
Sep 14Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?
Mar 12Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay
Feb 22Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 07Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain
Jan 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?
Dec 16Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Nov 28Could The Morepen Laboratories Limited (NSE:MOREPENLAB) Ownership Structure Tell Us Something Useful?
Nov 09Can You Imagine How Morepen Laboratories' (NSE:MOREPENLAB) Shareholders Feel About The 75% Share Price Increase?
Oct 13Morepen Laboratories Limited's (NSE:MOREPENLAB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Sep 17Morepen Laboratories Limited's (NSE:MOREPENLAB) Earnings Haven't Escaped The Attention Of Investors
Aug 26Is Now The Time To Put Morepen Laboratories (NSE:MOREPENLAB) On Your Watchlist?
Aug 19We Think Morepen Laboratories (NSE:MOREPENLAB) Can Stay On Top Of Its Debt
Jul 29Update: Morepen Laboratories (NSE:MOREPENLAB) Stock Gained 80% In The Last Five Years
Jul 08Financial Position Analysis
Short Term Liabilities: MOREPENLAB's short term assets (₹8.2B) exceed its short term liabilities (₹3.7B).
Long Term Liabilities: MOREPENLAB's short term assets (₹8.2B) exceed its long term liabilities (₹390.4M).
Debt to Equity History and Analysis
Debt Level: MOREPENLAB has more cash than its total debt.
Reducing Debt: MOREPENLAB's debt to equity ratio has reduced from 67.1% to 3.5% over the past 5 years.
Debt Coverage: MOREPENLAB's debt is well covered by operating cash flow (225.1%).
Interest Coverage: MOREPENLAB's interest payments on its debt are well covered by EBIT (58.4x coverage).